Be Cured For Life From Acne and Rosacea |
Home - Blog - Live Acne News - Links Page - Partners Page - Site Map
Acne Advice
   
|
| |
Uganda: Acupuncture - Needle Pricks to Relieve Pain?
AS a child, the whole hospital had to be mobilised to hold me before a nurse could inject me. I grew up fearing all needle piercing and shuddering at seeing someone else being pricked. That was until I came across a Chinese clinic that uses needles to relieve pain! The process is called acupuncture. Dr Liu Dezhog of the Chinese clinic near Kisementi in Kamwokya offered to illustrate how it works. I watched him insert several needles into the skin of his nurse to the depth of a few millimetres. .
Miss Fashionetta crowned during stylishly hot annual event The Beta Nu Omega chapter of Alpha Kappa Alpha Sorority hosted the 26th Annual Miss Fashionetta contest at the Joe L. Reed Acadome on Sunday afternoon. It was a pageantry-themed event of "grace and style" as guests from across the city joined friends from around the state to witness the crowning of the 2007 queen. The Miss Fashionetta presentation took place along an elevated runway constructed across the arena's floor. It was an elegant prelude to the "Stylishly Hot" 49th Annual Ebony Fashion Fair extravaganza, which followed the contest. Sponsored by Johnson Publishing Company, the tour of haute couture fashions makes a stop in the Capital City each year at the request of the local sorority -- one of more than 180 organizations around the country, in the Bahamas and the U.S.
DUSA Pharmaceuticals Announces Exclusive Agreeme nt with Daewoong ... WILMINGTON, Massachusetts, Jan. 8, 2007--(CCNMatthews) - DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA), announced today that it has entered into an exclusive marketing, distribution and supply agreement for certain Asian territories with Daewoong Pharmaceutical Co., Ltd., a market leader in prescription drugs in the region for dermatology. The agreement covers current and future uses of DUSA's proprietary Levulan(R) Kerastick(R) for photodynamic therapy (PDT) in dermatology. The Agreement, which has an initial term of ten years, (subject to earlier termination and extension provisions) will further expand the distribution of Levulan beyond the North, Central, and South American markets. Effective with the signing of the Agreement, Daewoong will complete final integration and submission of regulatory data to the Korean Food and Drug Administration with subsequent approval and market launch expected in 2008.
|